Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C27H25BF2N2O6S |
| Molecular Weight | 554.37 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CNC(=O)C1=C(OC2=C1C=C(C3CC3)C(=C2)N(CC4=CC=C(B(O)O)C(F)=C4)S(C)(=O)=O)C5=CC=C(F)C=C5
InChI
InChIKey=GDSKPIAEYNJODX-UHFFFAOYSA-N
InChI=1S/C27H25BF2N2O6S/c1-31-27(33)25-20-12-19(16-4-5-16)23(13-24(20)38-26(25)17-6-8-18(29)9-7-17)32(39(2,36)37)14-15-3-10-21(28(34)35)22(30)11-15/h3,6-13,16,34-35H,4-5,14H2,1-2H3,(H,31,33)
| Molecular Formula | C27H25BF2N2O6S |
| Molecular Weight | 554.37 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:51:28 UTC 2023
by
admin
on
Sat Dec 16 11:51:28 UTC 2023
|
| Record UNII |
6G04C5ZNQJ
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
53354790
Created by
admin on Sat Dec 16 11:51:28 UTC 2023 , Edited by admin on Sat Dec 16 11:51:28 UTC 2023
|
PRIMARY | |||
|
6G04C5ZNQJ
Created by
admin on Sat Dec 16 11:51:28 UTC 2023 , Edited by admin on Sat Dec 16 11:51:28 UTC 2023
|
PRIMARY | |||
|
1331942-30-3
Created by
admin on Sat Dec 16 11:51:28 UTC 2023 , Edited by admin on Sat Dec 16 11:51:28 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
GSK2485852 (referred to here as GSK5852) is a hepatitis C virus (HCV) NS5B polymerase inhibitor with 50% effective concentrations (EC50s) in the low nanomolar range in the genotype 1 and 2 subgenomic replicon system as well as the infectious HCV cell culture system. We have characterized the antiviral activity of GSK5852 using chimeric replicon systems with NS5B genes from additional genotypes as well as NS5B sequences from clinical isolates of patients infected with HCV of genotypes 1a and 1b. The inhibitory activity of GSK5852 remained unchanged in these intergenotypic and intragenotypic replicon systems. GSK5852 furthermore displays an excellent resistance profile and shows a <5-fold potency loss across the clinically important NS5B resistance mutations P495L, M423T, C316Y, and Y448H. GSK5852 was more potent than HCV-796, an earlier inhibitor in this class, and showed greater reductions in HCV RNA during long-term treatment of replicons. GSK5852 is similar to HCV-796 in its activity against multiple genotypes, but its superior resistance profile suggests that it could be an attractive component of an all-oral regimen for treating HCV.
|
||
|
ACTIVE MOIETY |
Originator: GlaxoSmithKline; Class: Antiviral; Mechanism of Action: Hepatitis C virus NS 5 protein inhibitor; Orphan Drug Status: No; On Fast track: No; Highest Development Phase: No development reported for Hepatitis C; Most Recent Events: 16 Jul 2016 No recent reports of development identified for phase-I development in Hepatitis-C(Combination therapy) in USA (IV), 28 Feb 2011 Phase-I clinical trials in Hepatitis C in USA (IV)
|
